tislelizumab + BGB-15025

**tislelizumab + BGB-15025** is an investigational combination therapy for cancer, most notably advanced solid tumors and non-small cell lung cancer. Tislelizumab is a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1/PD-L2 and thereby improving antitumor immune responses. BGB-15025 is a small molecule inhibitor that selectively and potently inhibits hematopoietic progenitor kinase 1 (HPK1), a negative regulator of T cell receptor signaling, enhancing T cell activation and potentially augmenting the efficacy of immune checkpoint inhibitors like PD-1 antibodies. The combination is being actively developed in phase 1 and phase 2 clinical studies, as preclinical data showed that BGB-15025 enhances the antitumor activity of anti-PD-1 antibodies including tislelizumab. Developed and manufactured by BeiGene (BGB-15025’s originator and developer), the combination is given as oral BGB-15025 plus intravenous tislelizumab for oncologic indications, especially advanced solid tumors and non-small cell lung cancer[2][3][4][5][6].

Brand names

Tevimbra (for tislelizumab)